Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
about
SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.Genome-wide DNA methylation analysis identifies candidate epigenetic markers and drivers of hepatocellular carcinoma.ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers.Hypermethylation of MDFI promoter with NSCLC is specific for females, non-smokers and people younger than 65.
P2860
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
@ast
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
@en
type
label
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
@ast
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
@en
prefLabel
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
@ast
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
@en
P2093
P2860
P50
P1476
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
@en
P2093
Adi F Gazdar
Adwait Sathe
Boning Gao
Carmen Behrens
John D Minna
Junya Fujimoto
Luc Girard
Michael Q Zhang
Neda Kalhor
P2860
P304
P356
10.1016/J.JTHO.2015.11.004
P577
2015-12-24T00:00:00Z